What Should
I Know Before
Starting
YIMMUGO^®?

What Should I Know
Before Starting YIMMUGO^®?

IMPORTANT SAFETY INFORMATION

YIMMUGO may cause:

• Blood clots (thrombosis). Blood clots may occur in people taking Ig intravenous (IGIV) products, including YIMMUGO. You may be at greater risk for blood clots if you are older, sit or lie for long periods, have a clotting condition or a history of blood clots, take estrogen, have a central catheter, have thick blood, and/or if you have other conditions that put you at risk for cardiovascular disease. Blood clots may occur even if you do not have any of these risk factors. Your healthcare provider should monitor you for signs and symptoms of blood clotting.
• Impaired kidney function or kidney failure. IGIV products, particularly those that contain sugar (sucrose), have been associated with kidney dysfunction and damage, kidney failure, and death. Kidney damage and failure are more common in people receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose. You may be at greater risk for kidney failure if you have kidney disease, diabetes, are seriously dehydrated, overweight, take drugs that may damage your kidneys, or are over age 65. Your healthcare provider should monitor your kidney function before and periodically after your first infusion.

Do NOT use YIMMUGO if:

• You have a history of severe hypersensitivity or a history of allergic reactions to human Ig. Tell your healthcare provider if you have had a serious reaction to other medicines that contain human Ig or ask if you are not sure.
• You have an immunoglobulin A (IgA) deficiency, have antibodies to IgA, or have a hypersensitivity or a history of allergic reactions. Tell your healthcare provider if you have an IgA deficiency or ask if you are not sure.

WARNINGS AND PRECAUTIONS

• Severe allergic reactions may occur. People with IgA deficiency who have antibodies against IgA may be at greater risk of these reactions.
• Blood damage called hemolysis and hemolytic anemia can develop after treatment with YIMMUGO. Your healthcare provider should monitor you for signs and symptoms.
• If you are at risk of developing kidney damage or failure, your healthcare provider should monitor your kidney function before and periodically after your first infusion.
• You could experience higher-than-normal levels of protein in your blood, thick blood, or low sodium (salt) in your blood. This may prevent your blood from flowing easily and possibly lead to blood clots.
• Brain swelling called aseptic meningitis syndrome may occur infrequently with IGIV products, especially if you receive a high dose or a rapid infusion.
• Swelling of the lungs may occur following treatment. Your healthcare provider should monitor you for signs of lung damage. 
• YIMMUGO is made from human blood and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent.
• Be sure to tell your healthcare provider about your recent history of vaccinations. Live vaccines for diseases like measles, mumps, rubella, and varicella may not work as well while receiving YIMMUGO. Tell your healthcare provider that you are taking YIMMUGO before you receive any vaccination.

ADVERSE REACTIONS

The most common side effects of YIMMUGO were headache, upper respiratory tract infections, fatigue, nausea, and increased blood pressure. During treatment with YIMMUGO, be sure to tell your healthcare provider about any unusual symptoms you experience, as they may indicate a possible side effect.

To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-3KDRION (1-855-353-7466) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for complete prescribing details, including Boxed Warning.